Eaton Vance Management Nektar Therapeutics Transaction History

Eaton Vance Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $5,150 - $16,985	-1,238 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $4,819 - $8,192	-445 Reduced 26.44%	1,238 $0
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $2,352 - $3,391	-180 Reduced 9.66%	1,683 $4,000
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $2,659 - $3,284	161 Added 9.46%	1,863 $32,000
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $28,185 - $43,332	1,702 New	1,702 $34,000

Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $741,455 - $1.09 Million	-15,959 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $738,103 - $1.67 Million	15,959 New	15,959 $779,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $242M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.